After rejection, FDA approves Telix’s Pixclara, the first FET-PET imaging drug for brain cancer Read more →
GSK doubles down on Chimagen with $750M multiple myeloma wager Read more →
Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis Read more →
« All Events
February 4, 2025 @ 11:30 am
Presentations from the Olink team on the value of combining genomic and proteomic data for the best insights into human disease and development of new therapeutics, and more. After, enjoy lunch and networking.